Observed 1-year rates and corresponding 95% CIs for all-cause mortality, non-haemorrhagic stroke/SE and major bleeding by region and in all 35 countries in GARFIELD-AF
| Region | Outcome | ||
| Mortality | Non-haemorrhagic stroke/SE | Major bleeding | |
| Europe | 4.4 (4.2 to 4.6) | 1.2 (1.1 to 1.3) | 1.3 (1.2 to 1.4) |
| Asia | 2.8 (2.6 to 3.1) | 1.0 (0.9 to 1.2) | 0.9 (0.7 to 1.0) |
| Latin America | 5.5 (4.8 to 6.2) | 1.4 (1.1 to 1.8) | 1.3 (1.0 to 1.7) |
| North America | 5.9 (4.8 to 7.2) | 1.0 (0.6 to 1.6) | 2.9 (2.2 to 3.8) |
| Other countries | 6.0 (5.1 to 7.0) | 1.8 (1.3 to 2.4) | 1.3 (0.9 to 1.9) |
| All countries | 4.2 (4.0 to 4.4) | 1.2 (1.1 to 1.3) | 1.2 (1.1 to 1.3) |
GARFIELD-AF, Global Anticoagulant Registry in the FIELD-Atrial Fibrillation; SE, systemic embolism.